1、Global Healthcare Private Equity and M&A Report 2023|First Look This work is based on secondary market research,analysis of financial information available or provided to Bain&Company and a range of interviews with industry participants.Bain&Company has not independently verified any such informatio

2、n provided or available to Bain and makes no representation or warranty,express or implied,that such information is accurate or complete.Projected market and financial information,analyses and conclusions contained herein are based on the information described above and on Bain&Companys judgment,and

3、 should not be construed as definitive forecasts or guarantees of future performance or results.The information and analysis herein does not constitute advice of any kind,is not intended to be used for investment purposes,and neither Bain&Company nor any of its subsidiaries or their respective offic

4、ers,directors,shareholders,employees or agents accept any responsibility or liability with respect to the use of or reliance on any information or analysis contained in this document.This work is copyright Bain&Company and may not be published,transmitted,broadcast,copied,reproduced or reprinted in

5、whole or in part without the explicit written permission of Bain&Company.Copyright 2023 Bain&Company,Inc.All rights reserved.iGlobal Healthcare Private Equity and M&A Report 2023|First LookContentsHealthcare Private Equity Market 2022:The Year in Review and Outlook .1Healthcare Private Equity in a D

6、ownturn .9Life Sciences:White-Hot Competition to Win the Right Deals .181 1At a Glance Down but not out:The first half of 2022 saw a continuation of 2021s record-setting pace for healthcare private equity(HCPE)deal volume and deal value,and while geopolitical uncertainty,inflation,interest rate pres